Marco Gasparetto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Marco Gasparetto has a total of 323 co-authors. Here are the top co-authors by number of shared publications:
- Graziella Guariso
Department of Pediatrics, University of Padua, Italy
8 shared publications - Matthias Zilbauer
Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK
7 shared publications - Dror S. Shouval
Gray Faculty of Medical and Health Sciences Tel Aviv University Tel Aviv Israel
5 shared publications Graziella Guariso
Department of Women and Child Health, University of Padova, Padova, Italy
5 shared publications- Graziella Guariso
Graziella Guariso, University of Padova, 35100 Padova, Italy
5 shared publications - Iva Hojsak
Children's Hospital Zagreb University of Zagreb Medical School Zagreb Croatia
5 shared publications
Latest Publications
- 3 September 2026
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 20 (9)
Upadacitinib treatment in pediatric Crohn’s disease: 52-week outcomes of an international multicenter retrospective cohort study from the pediatric IBD Porto Group of ESPGHAN
Background and aims: Data on upadacitinib maintenance therapy in pediatric Crohn’s disease (CD) are scarce. We aimed to evaluate the effectiveness, safety, and dosing of upadacitinib as maintenance therapy in pediatric CD. Methods: Children treated with upadacitinib for maintenance of remission of active CD from 35 centers affiliated with the Porto Group of ESPGHAN were included in this retrospective cohort study. Data on demographic, clinical, laboratory, endoscopic, and imaging findings and on adverse events (AEs) were recorded over 52 weeks of follow-up. Results: A total of 120 children were included (91 receiving upadacitinib as monotherapy and 29 as combination advanced therapy, mean age 15.4 ± 2.5 years). Prior to upadacitinib induction, 119/120 (99%) children had been treated with biologic therapies, 104 (87%) with two or more biologics and 98 (82%) had failed both vedolizumab and ustekinumab. Clinical remission and corticosteroid-free clinical remission (CFR) were observed after upadacitinib induction in 77 (64%) and 72 (60%) children, respectively. By week 52, 74 (62%) children achieved both clinical remission and CFR, and CFR was sustained in 66 (55%) children. CFR with normal C-reactive protein levels was achieved in 50% of children and CFR with fecal calprotectin levels <150 µg/g was achieved in 33% of children by week 52. Fifty-three (44%) children sustained AEs, two of which were serious (severe acne and intestinal perforation). The most frequent AEs were acne (n = 23), hyperlipidemia (n = 18), and infections (n = 14). Conclusion: Upadacitinib is an effective maintenance therapy for refractory pediatric CD. Effectiveness should be weighed against the potential risks of AEs.
- 3 September 2026
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 20 (9)
Upadacitinib treatment in pediatric Crohn’s disease: 52-week outcomes of an international multicenter retrospective cohort study from the pediatric IBD Porto Group of ESPGHAN
Background and aims: Data on upadacitinib maintenance therapy in pediatric Crohn’s disease (CD) are scarce. We aimed to evaluate the effectiveness, safety, and dosing of upadacitinib as maintenance therapy in pediatric CD. Methods: Children treated with upadacitinib for maintenance of remission of active CD from 35 centers affiliated with the Porto Group of ESPGHAN were included in this retrospective cohort study. Data on demographic, clinical, laboratory, endoscopic, and imaging findings and on adverse events (AEs) were recorded over 52 weeks of follow-up. Results: A total of 120 children were included (91 receiving upadacitinib as monotherapy and 29 as combination advanced therapy, mean age 15.4 ± 2.5 years). Prior to upadacitinib induction, 119/120 (99%) children had been treated with biologic therapies, 104 (87%) with two or more biologics and 98 (82%) had failed both vedolizumab and ustekinumab. Clinical remission and corticosteroid-free clinical remission (CFR) were observed after upadacitinib induction in 77 (64%) and 72 (60%) children, respectively. By week 52, 74 (62%) children achieved both clinical remission and CFR, and CFR was sustained in 66 (55%) children. CFR with normal C-reactive protein levels was achieved in 50% of children and CFR with fecal calprotectin levels <150 µg/g was achieved in 33% of children by week 52. Fifty-three (44%) children sustained AEs, two of which were serious (severe acne and intestinal perforation). The most frequent AEs were acne (n = 23), hyperlipidemia (n = 18), and infections (n = 14). Conclusion: Upadacitinib is an effective maintenance therapy for refractory pediatric CD. Effectiveness should be weighed against the potential risks of AEs.
- 5 August 2026
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 20 (8)
Management of Pediatric Crohn’s Disease: an ECCO-ESPGHAN Guideline Update
Objective: To provide an updated, evidence-based European Crohn’s and Colitis Organisation [ECCO]–European Society for Paediatric Gastroenterology, Hepatology and Nutrition [ESPGHAN] guideline for the management, monitoring, and long-term care of pediatric Crohn’s disease [CD]. Methods: A multidisciplinary panel of 27 experts followed ECCO Standard Operating Procedures for guideline development. A systematic review of studies published between January 2018 and October 2024, with targeted updates through June 2025, was conducted across MEDLINE, EMBASE, and Cochrane Central. Evidence was graded using the Oxford Centre for Evidence-Based Medicine levels. Draft statements underwent two Delphi voting rounds involving the guideline panel, ECCO National Representatives, and an international sounding board; statements achieving ≥80% agreement were accepted. Results: This guideline provides updated recommendations across major domains of pediatric CD care, including risk stratification, treatment targets, induction and maintenance strategies, nutritional therapies, therapeutic drug monitoring, and the roles of imaging and endoscopy. High-risk patients should start anti-TNF therapy as first-line treatment, with proactive and reactive therapeutic drug monitoring to enhance efficacy. For low-risk luminal disease, exclusive enteral nutrition or the Crohn’s Disease Exclusion Diet with partial enteral nutrition are preferred induction options. Long-term management emphasizes achieving endoscopic remission, normal growth, improved quality of life, and reduction of bowel damage. This guideline also reviews emerging advanced therapies, including biologics and small molecules, which are increasingly used in practice but generally not yet approved for pediatric CD, to inform clinicians about their potential role. Conclusions: This updated ECCO–ESPGHAN guideline integrates new pediatric evidence with contemporary adult data and treat-to-target principles, providing practical recommendations to support personalized, multidisciplinary, and proactive management aimed at improving long-term outcomes in pediatric CD.
- 5 August 2026
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 20 (8)
Management of Pediatric Crohn’s Disease: an ECCO-ESPGHAN Guideline Update
Objective: To provide an updated, evidence-based European Crohn’s and Colitis Organisation [ECCO]–European Society for Paediatric Gastroenterology, Hepatology and Nutrition [ESPGHAN] guideline for the management, monitoring, and long-term care of pediatric Crohn’s disease [CD]. Methods: A multidisciplinary panel of 27 experts followed ECCO Standard Operating Procedures for guideline development. A systematic review of studies published between January 2018 and October 2024, with targeted updates through June 2025, was conducted across MEDLINE, EMBASE, and Cochrane Central. Evidence was graded using the Oxford Centre for Evidence-Based Medicine levels. Draft statements underwent two Delphi voting rounds involving the guideline panel, ECCO National Representatives, and an international sounding board; statements achieving ≥80% agreement were accepted. Results: This guideline provides updated recommendations across major domains of pediatric CD care, including risk stratification, treatment targets, induction and maintenance strategies, nutritional therapies, therapeutic drug monitoring, and the roles of imaging and endoscopy. High-risk patients should start anti-TNF therapy as first-line treatment, with proactive and reactive therapeutic drug monitoring to enhance efficacy. For low-risk luminal disease, exclusive enteral nutrition or the Crohn’s Disease Exclusion Diet with partial enteral nutrition are preferred induction options. Long-term management emphasizes achieving endoscopic remission, normal growth, improved quality of life, and reduction of bowel damage. This guideline also reviews emerging advanced therapies, including biologics and small molecules, which are increasingly used in practice but generally not yet approved for pediatric CD, to inform clinicians about their potential role. Conclusions: This updated ECCO–ESPGHAN guideline integrates new pediatric evidence with contemporary adult data and treat-to-target principles, providing practical recommendations to support personalized, multidisciplinary, and proactive management aimed at improving long-term outcomes in pediatric CD.
- Open Access
- 18 July 2025
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 81 (3) , 765-815
Management of paediatric ulcerative colitis, part 1: Ambulatory care—An updated evidence‐based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation
Objectives: Despite advances in the management of ambulatory paediatric ulcerative colitis (UC), challenges remain as many patients are refractory to therapy and some require colectomy. The aim of these guidelines is to provide an update on optimal care for UC through detailed recommendations and practice points. Methods: These guidelines are an update to those published in 2018 and are a joint effort of the Paediatric IBD Porto group of European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation. An extensive literature search with subsequent evidence appraisal using the Oxford methodology was performed, followed by three online voting sessions and a consensus face‐to‐face meeting. Thirty‐nine recommendations and 77 practice points were endorsed by the 25 experts with at least an 84% consensus rate. Results: Robust evidence‐based recommendations and detailed practice points are provided. In addition to reemphasising and updating the role of more ‘traditional’ UC therapies, these guidelines outline optimising the use of antitumour necrosis factor therapies and integrating newer biologics and small molecules, as well as supportive therapy, to improve outcomes and provide an updated management algorithm. Measurement and monitoring tools and decision aids are provided, and additional aspects, including nutritional support, extraintestinal manifestations, pouchitis, inflammatory bowel disease‐unclassified and patient support, are discussed. Some aspects, including surgery and thromboprophylaxis, are covered in the acute severe UC guidelines. Conclusions: These guidelines serve as an aid in managing children with UC through a combination of evidence‐based recommendations and more practical practice points in the ambulatory setting.
- 18 July 2025
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 81 (3) , 765-815
Open AccessManagement of paediatric ulcerative colitis, part 1: Ambulatory care—An updated evidence‐based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation
Objectives: Despite advances in the management of ambulatory paediatric ulcerative colitis (UC), challenges remain as many patients are refractory to therapy and some require colectomy. The aim of these guidelines is to provide an update on optimal care for UC through detailed recommendations and practice points. Methods: These guidelines are an update to those published in 2018 and are a joint effort of the Paediatric IBD Porto group of European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation. An extensive literature search with subsequent evidence appraisal using the Oxford methodology was performed, followed by three online voting sessions and a consensus face‐to‐face meeting. Thirty‐nine recommendations and 77 practice points were endorsed by the 25 experts with at least an 84% consensus rate. Results: Robust evidence‐based recommendations and detailed practice points are provided. In addition to reemphasising and updating the role of more ‘traditional’ UC therapies, these guidelines outline optimising the use of antitumour necrosis factor therapies and integrating newer biologics and small molecules, as well as supportive therapy, to improve outcomes and provide an updated management algorithm. Measurement and monitoring tools and decision aids are provided, and additional aspects, including nutritional support, extraintestinal manifestations, pouchitis, inflammatory bowel disease‐unclassified and patient support, are discussed. Some aspects, including surgery and thromboprophylaxis, are covered in the acute severe UC guidelines. Conclusions: These guidelines serve as an aid in managing children with UC through a combination of evidence‐based recommendations and more practical practice points in the ambulatory setting.
- 17 June 2025
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 81 (3) , 816-851
Management of paediatric ulcerative colitis, part 2: Acute severe colitis—An updated evidence‐based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organization
Acute severe colitis (ASC) is a relatively frequent manifestation in children with ulcerative colitis and one of the few emergencies in paediatric gastroenterology. A standardized proactive approach based on tight monitoring and timely medical and surgical interventions may improve patients' outcomes. We aimed to update the previous ASC guidelines using detailed recommendations and practice points, based on a systematic review of the literature and consensus of experts. These guidelines update is a joint effort of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organization. A systematic search was performed in Pubmed Ovid Medline, Embase and Cochrane databases using 13 predefined PICO (patient, intervention, comparison, outcomes) based questions and 30 non‐PICO based questions. Grading methodology was based on the Oxford Centre for Evidence‐Based Medicine—Levels of evidence. The questions were addressed by working subgroups following an iterative consensus voting process, including three online voting meetings and one face‐to‐face meeting. A total of 36 recommendations and 72 practice points were endorsed with a consensus rate of at least 88% for all statements, regarding initial evaluation, monitoring, medical and surgical treatment of ASC in children. Several topics have been revised since the previous 2018 guidelines and differ from corresponding published adult guidelines. These guidelines present a comprehensive overview of the management of ASC in children, offering practical recommendations and practice points aiming to standardize clinical and surgical treatment and improve outcomes of this severe scenario.
- 17 June 2025
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 81 (3) , 816-851
Management of paediatric ulcerative colitis, part 2: Acute severe colitis—An updated evidence‐based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organization
Acute severe colitis (ASC) is a relatively frequent manifestation in children with ulcerative colitis and one of the few emergencies in paediatric gastroenterology. A standardized proactive approach based on tight monitoring and timely medical and surgical interventions may improve patients' outcomes. We aimed to update the previous ASC guidelines using detailed recommendations and practice points, based on a systematic review of the literature and consensus of experts. These guidelines update is a joint effort of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organization. A systematic search was performed in Pubmed Ovid Medline, Embase and Cochrane databases using 13 predefined PICO (patient, intervention, comparison, outcomes) based questions and 30 non‐PICO based questions. Grading methodology was based on the Oxford Centre for Evidence‐Based Medicine—Levels of evidence. The questions were addressed by working subgroups following an iterative consensus voting process, including three online voting meetings and one face‐to‐face meeting. A total of 36 recommendations and 72 practice points were endorsed with a consensus rate of at least 88% for all statements, regarding initial evaluation, monitoring, medical and surgical treatment of ASC in children. Several topics have been revised since the previous 2018 guidelines and differ from corresponding published adult guidelines. These guidelines present a comprehensive overview of the management of ASC in children, offering practical recommendations and practice points aiming to standardize clinical and surgical treatment and improve outcomes of this severe scenario.
- Open Access
- 14 May 2025
- Published by Elsevier in The Lancet Digital Health
- Vol. 7 (5) , 100843
Efficacy of digital health technologies in the management of inflammatory bowel disease: an umbrella review
- 14 May 2025
- Published by Elsevier in The Lancet Digital Health
- Vol. 7 (5) , 100843
Open AccessEfficacy of digital health technologies in the management of inflammatory bowel disease: an umbrella review
- 28 November 2024
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 19 (5)
Upadacitinib for Induction of Remission in Pediatric Ulcerative Colitis: An International Multicenter Study
Background and Aims: Data on upadacitinib therapy in children with ulcerative colitis (UC) or unclassified inflammatory bowel disease (IBD-U) are scarce. We aimed to evaluate the effectiveness and safety of upadacitinib as an induction therapy in pediatric UC or IBD-U. Methods: In this multicenter retrospective study, children treated with upadacitinib for induction of remission of active UC or IBD-U from 30 centers worldwide were enrolled. Demographic, clinical, and laboratory data, as well as adverse events (AEs), were recorded at Week 8 post-induction. Results: One hundred children were included (90 UC and 10 IBD-U, median age 15.6 [interquartile range 13.3–17.1] years). Ninety-eight were previously treated with biologic therapies, and 76 were treated with ≥2 biologics. At the end of the 8-week induction period, clinical response, clinical remission, and corticosteroid-free clinical remission (CFR) were observed in 84%, 62%, and 56% of the children, respectively. Normal C-reactive protein and fecal calprotectin (FC) <150 mcg/g were achieved in 75% and 50%, respectively. Combined CFR and FC remission was observed in 18/46 (39%) children with available data at 8 weeks. Adverse events were recorded in 37 children, including 1 serious AE of an appendiceal neuroendocrine tumor. The most frequent AEs were hyperlipidemia (n = 13), acne (n = 12), and infections (n = 10, 5 of whom with herpes viruses). Conclusions: Upadacitinib is an effective induction therapy for refractory pediatric UC and IBD-U. Efficacy should be weighed against the potential risks of AEs.
- 28 November 2024
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 19 (5)
Upadacitinib for Induction of Remission in Pediatric Ulcerative Colitis: An International Multicenter Study
Background and Aims: Data on upadacitinib therapy in children with ulcerative colitis (UC) or unclassified inflammatory bowel disease (IBD-U) are scarce. We aimed to evaluate the effectiveness and safety of upadacitinib as an induction therapy in pediatric UC or IBD-U. Methods: In this multicenter retrospective study, children treated with upadacitinib for induction of remission of active UC or IBD-U from 30 centers worldwide were enrolled. Demographic, clinical, and laboratory data, as well as adverse events (AEs), were recorded at Week 8 post-induction. Results: One hundred children were included (90 UC and 10 IBD-U, median age 15.6 [interquartile range 13.3–17.1] years). Ninety-eight were previously treated with biologic therapies, and 76 were treated with ≥2 biologics. At the end of the 8-week induction period, clinical response, clinical remission, and corticosteroid-free clinical remission (CFR) were observed in 84%, 62%, and 56% of the children, respectively. Normal C-reactive protein and fecal calprotectin (FC) <150 mcg/g were achieved in 75% and 50%, respectively. Combined CFR and FC remission was observed in 18/46 (39%) children with available data at 8 weeks. Adverse events were recorded in 37 children, including 1 serious AE of an appendiceal neuroendocrine tumor. The most frequent AEs were hyperlipidemia (n = 13), acne (n = 12), and infections (n = 10, 5 of whom with herpes viruses). Conclusions: Upadacitinib is an effective induction therapy for refractory pediatric UC and IBD-U. Efficacy should be weighed against the potential risks of AEs.
- Open Access
- 4 January 2024
- Published by Wiley in JPGN Reports
- Vol. 5 (1) , 17-28
The impact of age, disease severity, and BMI on bone health and growth in children and young people with Crohn's disease
The objective of this study was to explore the correlation between paediatric Crohn's disease (CD) characteristics, bone health and growth parameters at diagnosis and follow‐up. Retrospective data was collected for 47 children aged 4–16 who were newly diagnosed with CD between January 2018 and December 2019. Mean follow‐up time was 2.5 years. Eleven (24%) children had growth delay at diagnosis, which persisted in 4 (44%) of 9 recorded children at follow‐up. Of the 35 children tested, 20 (57%) had inadequate Vitamin D levels (<50 mmol/L) at diagnosis. Thirty‐seven (79%) children had a dual‐energy X‐ray absorptiometry scan at diagnosis, with 20 of them having at least 1 low Z‐score. Children with poorer bone mineral density and bone mineral concentration Z‐scores for age had a younger age at diagnosis (p = .042 and p = .021), more severe disease (p = .04 and p = .029) and a lower BMI (p < .001) at diagnosis. Children diagnosed with CD ≥11 years had a lower‐than‐expected height velocity (p < .0001 and p < .001). Multivariate regression analysis demonstrated an older age of diagnosis was a significant predictor of a lower height velocity at follow‐up. Disease severity and age of diagnosis are important CD‐related factors that influence bone health and growth. Vitamin D is an accessible component that if optimised can improve all three factors. Monitoring and optimising each aspect systematically has the potential to enable children to achieve their bone health and growth potentials. Growth failure occurs in up to 85% of children diagnosed with Crohn's disease and persists in up to 40%. Vitamin D plays a role in bone health (BH), growth, and intestinal inflammation. Chronic inflammation and undernutrition are key factors behind poor BH and growth failure. Children with poorer BH are younger, have more severe disease and a lower body mass index at diagnosis. An older age of diagnosis is an independent predictor of lower‐than‐expected height velocity in the future.
- 4 January 2024
- Published by Wiley in JPGN Reports
- Vol. 5 (1) , 17-28
Open AccessThe impact of age, disease severity, and BMI on bone health and growth in children and young people with Crohn's disease
The objective of this study was to explore the correlation between paediatric Crohn's disease (CD) characteristics, bone health and growth parameters at diagnosis and follow‐up. Retrospective data was collected for 47 children aged 4–16 who were newly diagnosed with CD between January 2018 and December 2019. Mean follow‐up time was 2.5 years. Eleven (24%) children had growth delay at diagnosis, which persisted in 4 (44%) of 9 recorded children at follow‐up. Of the 35 children tested, 20 (57%) had inadequate Vitamin D levels (<50 mmol/L) at diagnosis. Thirty‐seven (79%) children had a dual‐energy X‐ray absorptiometry scan at diagnosis, with 20 of them having at least 1 low Z‐score. Children with poorer bone mineral density and bone mineral concentration Z‐scores for age had a younger age at diagnosis (p = .042 and p = .021), more severe disease (p = .04 and p = .029) and a lower BMI (p < .001) at diagnosis. Children diagnosed with CD ≥11 years had a lower‐than‐expected height velocity (p < .0001 and p < .001). Multivariate regression analysis demonstrated an older age of diagnosis was a significant predictor of a lower height velocity at follow‐up. Disease severity and age of diagnosis are important CD‐related factors that influence bone health and growth. Vitamin D is an accessible component that if optimised can improve all three factors. Monitoring and optimising each aspect systematically has the potential to enable children to achieve their bone health and growth potentials. Growth failure occurs in up to 85% of children diagnosed with Crohn's disease and persists in up to 40%. Vitamin D plays a role in bone health (BH), growth, and intestinal inflammation. Chronic inflammation and undernutrition are key factors behind poor BH and growth failure. Children with poorer BH are younger, have more severe disease and a lower body mass index at diagnosis. An older age of diagnosis is an independent predictor of lower‐than‐expected height velocity in the future.
- 1 July 2023
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 17 (12) , 1939-1948
Clinical Features and Natural History of Paediatric Patients with Ulcerative Proctitis: A Multicentre Study from the Paediatric IBD Porto Group of ESPGHAN
Background and Aims: Ulcerative proctitis [UP] is an uncommon presentation in paediatric patients with ulcerative colitis. We aimed to characterize the clinical features and natural history of UP in children, and to identify predictors of poor outcomes. Methods: This was a retrospective study involving 37 sites affiliated with the IBD Porto Group of ESPGHAN. Data were collected from patients aged <18 years diagnosed with UP between January 1, 2016 and December 31, 2020. Results: We identified 196 patients with UP (median age at diagnosis 14.6 years [interquartile range, IQR 12.5–16.0]), with a median follow-up of 2.7 years [IQR 1.7–3.8]. The most common presenting symptoms were bloody stools [95%], abdominal pain [61%] and diarrhoea [47%]. At diagnosis, the median paediatric ulcerative colitis activity index [PUCAI] score was 25 [IQR 20–35], but most patients exhibited moderate–severe endoscopic inflammation. By the end of induction, 5-aminosalicylic acid administration orally, topically or both resulted in clinical remission rates of 48%, 48%, and 73%, respectively. The rates of treatment escalation to biologics at 1, 3, and 5 years were 10%, 22%, and 43%, respectively. In multivariate analysis, the PUCAI score at diagnosis was significantly associated with initiation of systemic steroids, or biologics, and subsequent acute severe colitis events and inflammatory bowel disease-associated admission, with a score ≥35 providing an increased risk for poor outcomes. By the end of follow-up, 3.1% of patients underwent colectomy. Patients with UP that experienced proximal disease progression during follow-up [48%] had significantly higher rates of a caecal patch at diagnosis and higher PUCAI score by the end of induction, compared to those without progression. Conclusion: Paediatric patients with UP exhibit high rates of treatment escalation and proximal disease extension.
- 1 July 2023
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 17 (12) , 1939-1948
Clinical Features and Natural History of Paediatric Patients with Ulcerative Proctitis: A Multicentre Study from the Paediatric IBD Porto Group of ESPGHAN
Background and Aims: Ulcerative proctitis [UP] is an uncommon presentation in paediatric patients with ulcerative colitis. We aimed to characterize the clinical features and natural history of UP in children, and to identify predictors of poor outcomes. Methods: This was a retrospective study involving 37 sites affiliated with the IBD Porto Group of ESPGHAN. Data were collected from patients aged <18 years diagnosed with UP between January 1, 2016 and December 31, 2020. Results: We identified 196 patients with UP (median age at diagnosis 14.6 years [interquartile range, IQR 12.5–16.0]), with a median follow-up of 2.7 years [IQR 1.7–3.8]. The most common presenting symptoms were bloody stools [95%], abdominal pain [61%] and diarrhoea [47%]. At diagnosis, the median paediatric ulcerative colitis activity index [PUCAI] score was 25 [IQR 20–35], but most patients exhibited moderate–severe endoscopic inflammation. By the end of induction, 5-aminosalicylic acid administration orally, topically or both resulted in clinical remission rates of 48%, 48%, and 73%, respectively. The rates of treatment escalation to biologics at 1, 3, and 5 years were 10%, 22%, and 43%, respectively. In multivariate analysis, the PUCAI score at diagnosis was significantly associated with initiation of systemic steroids, or biologics, and subsequent acute severe colitis events and inflammatory bowel disease-associated admission, with a score ≥35 providing an increased risk for poor outcomes. By the end of follow-up, 3.1% of patients underwent colectomy. Patients with UP that experienced proximal disease progression during follow-up [48%] had significantly higher rates of a caecal patch at diagnosis and higher PUCAI score by the end of induction, compared to those without progression. Conclusion: Paediatric patients with UP exhibit high rates of treatment escalation and proximal disease extension.
- 27 July 2022
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 59 (7) , 928
An unexpected percutaneous gastro‐jejunostomy obstruction
- 27 July 2022
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 59 (7) , 928
An unexpected percutaneous gastro‐jejunostomy obstruction
P310 Research priorities in digital technology for adolescents and young persons with inflammatory bowel disease
Introduction Evolution of digital technologies (DT) offers significant opportunities to transform inflammatory bowel disease (IBD) care. A James Lind Alliance (JLA) Priority Setting Partnership (PSP) aims to identify research priorities for DT in IBD. A survey was designed to identify unanswered questions or evidence uncertainties in the use of DT for adolescents and young persons with IBD. Methods PSP meetings were held with key stakeholders within a Steering Group (SG) consisting of: paediatric and adult gastroenterologists with an interest in adolescent and young person care from BSPGHAN and BSG respectively; IBD specialist nurses; representatives from Crohn’s in Childhood Research Association (CICRA) and Crohn’s and Colitis UK (CCUK) charities; patient and parent representatives. The survey was designed through an iterative process, considered complete when there was saturation of changes and approved by all stakeholders. A pilot survey with a feedback questionnaire resulted in additional minor changes to the structure and content and provided examples of research priorities to guide participants. Results A final survey consisting of three sections was approved by the SG. The first captures the respondent’s role and connection with IBD. The second invites them to submit questions about DT in two areas: DT to support their condition and improve IBD care, and DT to improve communication with the healthcare team. Open-ended questions are used to allow elaboration of answers with examples generated from the pilot survey to assist respondents articulate research questions. An optional last section captures demographic information not linked to responses in previous sections. Conclusions A survey (Figure 1) was developed and piloted as a first step to identify unanswered questions. Research priorities will be identified using the JLA methodology to galvanise DT research that may translate into improved disease outcomes and quality of life.
P310 Research priorities in digital technology for adolescents and young persons with inflammatory bowel disease
Introduction Evolution of digital technologies (DT) offers significant opportunities to transform inflammatory bowel disease (IBD) care. A James Lind Alliance (JLA) Priority Setting Partnership (PSP) aims to identify research priorities for DT in IBD. A survey was designed to identify unanswered questions or evidence uncertainties in the use of DT for adolescents and young persons with IBD. Methods PSP meetings were held with key stakeholders within a Steering Group (SG) consisting of: paediatric and adult gastroenterologists with an interest in adolescent and young person care from BSPGHAN and BSG respectively; IBD specialist nurses; representatives from Crohn’s in Childhood Research Association (CICRA) and Crohn’s and Colitis UK (CCUK) charities; patient and parent representatives. The survey was designed through an iterative process, considered complete when there was saturation of changes and approved by all stakeholders. A pilot survey with a feedback questionnaire resulted in additional minor changes to the structure and content and provided examples of research priorities to guide participants. Results A final survey consisting of three sections was approved by the SG. The first captures the respondent’s role and connection with IBD. The second invites them to submit questions about DT in two areas: DT to support their condition and improve IBD care, and DT to improve communication with the healthcare team. Open-ended questions are used to allow elaboration of answers with examples generated from the pilot survey to assist respondents articulate research questions. An optional last section captures demographic information not linked to responses in previous sections. Conclusions A survey (Figure 1) was developed and piloted as a first step to identify unanswered questions. Research priorities will be identified using the JLA methodology to galvanise DT research that may translate into improved disease outcomes and quality of life.